HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Feb. 13, 2006--Nymox Pharmaceutical Corporation (NASDAQ:NYMX) announced today that it has entered into an agreement with Lab21 Limited for the provision of Nymox’s AlzheimAlert(TM) testing in the U.K. AlzheimAlert(TM) is Nymox’s unique, proprietary product that provides physicians with a valuable tool for the diagnosis of Alzheimer’s disease (AD) by measuring levels of a brain protein in patients’ urine samples. Lab21 provides technically advanced clinical testing services for the pharmaceutical industry and healthcare providers in the U.K. through its extensive, fully accredited laboratory facilities in Cambridge, England. Lab21’s current services include unique know-how in antiviral drug discovery plus a portfolio of cutting-edge molecular diagnostics, viral characterisation, pharmacogenetic tests, and patient profiling.
